Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma R&D growth spurt

Executive Summary

Led by Pfizer, the pharmaceutical sector has become the top R&D investor worldwide, surpassing the technology, hardware and equipment sector, according to the European Commission. Pfizer overtook Ford for the top spot, spending $8.18 billion last year on R&D, a 2.1 percent increase from 2005. Of the top 50 R&D spenders on the list, 13 are pharmaceutical firms. Overall, pharma spent $99.4 billion on R&D last year, and far surpassed other major sectors in terms of R&D expenditures as a percentage of sales. The European Commission noted a strong increase in R&D investment for several pharmaceutical companies: Merck (24.3%), AstraZeneca (15.5%), Roche (15.5%), Johnson & Johnson (12.9%), Novartis (10.7%) and GlaxoSmithKline (10%)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel